Pharmaceuticals 26 May 2026 - 2 June 2026

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote
·······

Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote

Ligand Pharmaceuticals shares moved higher on Tuesday. The stock outperformed biotech funds, which took a hit, as investors focused on upcoming management meetings and stayed active trading Ligand’s pending XOMA Royalty deal. The Nasdaq-listed stock was trading at $233.11 as of 12:53 p.m. EDT, up 1.4%. The SPDR S&P Biotech ETF was down 3.8% and the iShares Nasdaq Biotechnology ETF slid 3.0%. The SPY ETF, which tracks the S&P 500, edged up 0.1% and the QQQ, which follows the Nasdaq 100, added 0.4%.
June 2, 2026
Journey Medical Shares Drop—DERM’s 2026 Outlook Hinges on Emrosi Trial
····

Journey Medical Shares Drop—DERM’s 2026 Outlook Hinges on Emrosi Trial

Journey Medical Corp was down 3.5% at $6.09 late Monday, putting the company's market cap around $166 million. The Scottsdale-based maker of dermatology drugs trailed the SPDR S&P Biotech ETF, which slipped 2.2%. No new company statement has landed in the past two days. Journey’s investor page still shows the last update as May 19, when it flagged its slot at A.G.P.’s Annual Virtual Healthcare Conference. Before that, the site posted Journey’s May 13 Q1 earnings.
June 2, 2026
Alnylam Near 52-Week Low With Amvuttra in Focus
····

Alnylam Near 52-Week Low With Amvuttra in Focus

Alnylam Pharmaceuticals dropped 2.16% to finish Monday at $295.47, and was just above that level in after-hours action. The Cambridge, Massachusetts biotech is sitting about 4% above its 52-week low, down about 40% from an October high. Shares moved in a $295.14 to $303.98 range for the day. The market lost ground on that news. U.S. stocks were mostly higher, with Reuters saying the S&P 500 was up 0.43% and the Nasdaq up 0.69% as tech names gained. Only technology and energy were in the green out of the 11 S&P sectors. Alnylam’s story is different, though—a heart-drug stock that’s still stuck at the low end of its one-year range.
June 1, 2026
MediWound Shares Slide This Week; BARDA Moves in Focus
····

MediWound Shares Slide This Week; BARDA Moves in Focus

MediWound Ltd. closed Friday at $14.33, off 1.6% for the day and down about 13.6% since May 22. The market cut its outlook for the wound-care drug company’s near-term revenue. Shares slid hardest on Wednesday, dropping 14.1% on 451,100 shares traded. MediWound shares moved lower even as the Nasdaq Composite finished higher on Friday, ending its best two-month run in over 20 years. The selloff stands out, pointing to questions around the company and not a broad biotech slump.
May 30, 2026
Celcuity Rises Ahead of ASCO Update With FDA Deadline Pressing
····

Celcuity Rises Ahead of ASCO Update With FDA Deadline Pressing

Celcuity Inc. shares gained late Friday, topping the biotech sector as the company heads toward several cancer-drug updates, investor meetings, and an upcoming FDA decision date. Shares of the Minneapolis-based biotech traded at $132.88, adding $2.14, or around 1.6% on the day. The SPDR S&P Biotech ETF edged up roughly 0.5%. The iShares Nasdaq Biotechnology ETF was little changed.
May 30, 2026
Cumberland Pharma Stock Rises After China Antibiotic Launch — Why Investors Are Watching
····

Cumberland Pharma Stock Rises After China Antibiotic Launch — Why Investors Are Watching

Cumberland Pharmaceuticals Inc. shares rose on Friday after the company said its Vibativ antibiotic had launched in China through partner SciClone Pharmaceuticals, giving the small U.S. drugmaker a new overseas commercial trigger a month after it agreed to sell its branded U.S. portfolio to Apotex. Cumberland was last quoted at $6.15, up 21 cents from its previous close, after trading between $5.95 and $6.25. Its market value, or stock-market worth, stood at about $92 million.
May 29, 2026
vTv Therapeutics Drops as Diabetes Study Date Approaches
····

vTv Therapeutics Drops as Diabetes Study Date Approaches

vTv Therapeutics Inc. shares fell 1.1% to $33.14 Friday afternoon, lagging behind a stronger biotech market with investors waiting on further news from its diabetes program. The SPDR S&P Biotech ETF gained around 0.8%, and the iShares Nasdaq Biotechnology ETF was up 0.2%. vTv shares are trading now mostly on prospects for cadisegliatin, its oral candidate being trialed as an add-on to insulin in type 1 diabetes. The company said in a May 13 update that it still expects to finish enrolling its Phase 3 CATT1 study in the third quarter of 2026.
May 29, 2026
Aurinia Stock Dips as Traders Eye Lupkynis Data
····

Aurinia Stock Dips as Traders Eye Lupkynis Data

Aurinia Pharmaceuticals Inc. slid in Friday’s Nasdaq session. The stock lagged a mixed biotech sector. Traders were watching the Lupkynis sales outlook. There wasn’t a new press release from the company. The stock traded 0.9% lower at $15.21, giving it a market cap near $2.1 billion. The SPDR S&P Biotech ETF edged up around 0.1%. The iShares Nasdaq Biotechnology ETF was off roughly 0.1%.
May 29, 2026
Pliant Therapeutics Rises $1.25 Ahead of ASCO Conference
····

Pliant Therapeutics Rises $1.25 Ahead of ASCO Conference

Pliant Therapeutics Inc. moved up in late trading Thursday, last seen at $1.25, up roughly 1.2% from the previous close. Market cap hovered around $77 million. Volume was a bit over 210,000 shares. The move came once the regular Nasdaq session closed. Nasdaq’s regular hours are 9:30 a.m. to 4 p.m. ET, then after-hours trading goes till 8 p.m. ET. After-hours is any trading after the main session, usually with less liquidity.
May 29, 2026
Viking Therapeutics Stock Draws Wall Street Attention with Obesity Pill Competition Growing
····

Viking Therapeutics Stock Draws Wall Street Attention with Obesity Pill Competition Growing

Viking Therapeutics Inc. shares picked up 1.7% to $32.19 on Thursday afternoon. Lake Street rolled out new coverage with a bullish call on the obesity-drug company. The stock moved in a range of $31.39 to $32.22. Market cap was around $3.72 billion. Viking remains a clinical-stage drugmaker, with most of its worth tied to treatments in development rather than products on the market. Investors are looking at its obesity drug VK2735, now heading for Phase 3 trials, to see if it can make it through the final testing needed for approval as obesity treatments keep moving toward oral and injectable options.
May 28, 2026
NewAmsterdam Pharma Stock Rises as Fresh Filing Puts Its $4.3 Billion Drug Bet in Focus
····

NewAmsterdam Pharma Stock Rises as Fresh Filing Puts Its $4.3 Billion Drug Bet in Focus

NewAmsterdam Pharma Company N.V. shares head into Thursday’s U.S. session with a fresh insider filing in the tape and the stock still priced around the next tests for obicetrapib, its late-stage cholesterol drug. NAMS last traded at $36.56, up about 1.3% from its previous close, with a market value near $4.27 billion. That move stood out against a quiet broader tape. A Reuters market-data snapshot showed the S&P 500 up 0.02% and the Nasdaq Composite up 0.07%, leaving the company’s shares moving more on its own news flow than on index strength.
May 28, 2026
Maze Therapeutics Heads for June With Wall Street Watching Kidney Drug
····

Maze Therapeutics Heads for June With Wall Street Watching Kidney Drug

Maze Therapeutics stock was little changed in Thursday’s premarket trade as investors shrugged off a sparse update from the company. Focus is already shifting to June, when investor events could provide more detail on Maze’s main kidney-disease program. The stock fell about 1.2% to $26.05 in recent trade, leaving the South San Francisco biotech's market value near $1.4 billion. Biotech shares elsewhere traded higher. The SPDR S&P Biotech ETF was up 0.8%. The iShares Nasdaq Biotechnology ETF added 0.3%.
May 28, 2026
LeonaBio Gets $20 Price Target Ahead of June Pipeline Test
····

LeonaBio Gets $20 Price Target Ahead of June Pipeline Test

• Piper Sandler launched coverage on LeonaBio with an overweight rating and a $20 price target. Analyst Kelsey Goodwin is the lead on the name.• LeonaBio said it’s set to present ATH-1105 for ALS on June 3, and will join a trials panel in oncology on June 24.• Shares last traded at $9.81, up 1.45%, on volume a little above 51,000. Piper Sandler started coverage on LeonaBio Inc. with an overweight rating and a $20 target, giving the Nasdaq-listed biotech a new boost this week. The call comes ahead of LeonaBio’s scheduled medical-meeting appearances in June.
May 28, 2026
Alector Shares Up, Focus Turns to Pipeline After Setback
····

Alector Shares Up, Focus Turns to Pipeline After Setback

Alector Inc. shares moved higher Wednesday, climbing ahead of other biotech names. Traders came back to the small-cap neuroscience stock a few weeks after a fresh clinical setback shifted the focus to its earlier-stage pipeline. Shares rose 3.7% to $2.27 late in the morning, opening at $2.20 and hitting a session high at $2.27. The SPDR S&P Biotech ETF, often tracked for small-cap biotech stocks, was up 1.2%.
May 27, 2026
Arrowhead Gains 5% After Latest Plozasiran Update Puts Spotlight on Rare Disease Race
····

Arrowhead Gains 5% After Latest Plozasiran Update Puts Spotlight on Rare Disease Race

Arrowhead Pharmaceuticals stock climbed about 5% to $78.68 late Tuesday. The rise brought the company’s market cap to roughly $11.2 billion. Arrowhead released new plozasiran data at the European Atherosclerosis Society meeting in Athens. The company said results back using a 25-mg dose, without need for adjustment, in patients with moderate-to-severe kidney issues or moderate liver impairment. “This is an important step,” said Jennifer Hellawell, vice president of clinical development. The readout has new weight because plozasiran got its first FDA nod back in November. Redemplo cleared the agency for familial chylomicronemia syndrome, or FCS, a genetic disease that keeps people from breaking down triglycerides, the fat in blood. The FDA says a normal level is under 150 mg/dL—over 500
May 27, 2026
United Therapeutics Shares Up With Tyvaso Nearing FDA Milestone
····

United Therapeutics Shares Up With Tyvaso Nearing FDA Milestone

United Therapeutics shares gained 1.4% to $576.30 in early-afternoon trade Tuesday. The stock opened at $564.61 and reached as high as $576.99 intraday. Market cap was about $27.2 billion. Nasdaq opened again after the Memorial Day break, pushing broader stock indexes higher in early U.S. trading. Tech stocks took the lead, with the Nasdaq out in front. Growth-focused healthcare shares also got a lift compared to trading before the holiday.
May 26, 2026
BridgeBio shares slip as 2031 drug pricing risk pops up
····

BridgeBio shares slip as 2031 drug pricing risk pops up

BridgeBio Pharma shares slipped Tuesday after Raymond James lowered its rating on the genetic-medicine firm. The move puts more attention on market risk around Attruby, BridgeBio’s heart drug, as investors look ahead to insurers’ stance if a cheaper generic linked to Pfizer’s Vyndamax approaches. BridgeBio shares dropped 2.8% to $67.18 in late morning trade, putting its market cap near $13.1 billion. The stock hit a low of $66.57. The SPDR S&P Biotech ETF gained 1.1%, while the iShares Nasdaq Biotechnology ETF was up 0.4%. BridgeBio lagged the sector as U.S. equity markets came back after the Memorial Day holiday on Monday.
May 26, 2026
Adial Pharmaceuticals Stock Faces Crucial AD04 Funding Test After Holiday Break
····

Adial Pharmaceuticals Stock Faces Crucial AD04 Funding Test After Holiday Break

Adial Pharmaceuticals shares were indicated lower ahead of Tuesday’s open, with ADIL at $2.05 in premarket trading — the session before regular market hours — down 1.4% from the previous close of $2.08. U.S. exchanges were shut Monday for Memorial Day and were due to resume normal trading Tuesday. The move is small in dollar terms. It matters because Adial is not trading on sales momentum. It is trading on whether it can fund, partner or delay the next step for AD04, its lead drug candidate for alcohol use disorder.
May 26, 2026
Roivant stock set for new test after big move on drug data
·····

Roivant stock set for new test after big move on drug data

Roivant Sciences shares traded up in quiet premarket action Tuesday, showing a move after last week’s jump on drug data and the U.S. market holiday. The Nasdaq stock stood at $30.31 before the open, gaining 1.2% from Friday’s $29.96 close, with just 384 shares changing hands early. Timing is key. U.S. stock markets were shut for Memorial Day on Monday. Nasdaq’s regular hours are 9:30 a.m. to 4 p.m. Eastern, with premarket trading from 4 a.m. to 9:30 a.m. Eastern. Premarket is outside the main session and usually sees lighter liquidity.
May 26, 2026
1 2 3 4